GSK Joins Growing PD-1 SubQ Push With Alteogen Alliance Worth up to $285M+

Ahead of GSK are Bristol Myers Squibb and Merck, which have already won FDA approvals for subcutaneous formulations of their respective PD-1 blockers Opdivo and Keytruda.